The present invention concerns an extracorporeal circuit for removing CO.sub.2 from blood comprising a blood withdrawal line for withdrawing blood from the patient, a filtration unit for producing plasma water and a line for returning the blood to the patient, defining a main circuit; the extracorporeal circuit further comprises a decarbonating group comprising a secondary circuit for the recirculation of plasma water, means for removing a fraction of said plasma water, a CO.sub.2 exchanger, a cationic resin charged with H+ ions set upstream of the CO.sub.2 exchanger and adapted to generate acid plasma water, means for the infusion of the acid plasma water upstream of the CO.sub.2 exchanger and means for the infusion of ions in a solution downstream of the CO.sub.2 exchanger.

Provided herein are bedside systems and methods for performing customized cell-based therapies and treatments in a patient-connected, closed-loop continuous-flow manner, including cellular modifications and treatments, e.g., to produce chimeric antigen receptor-T (CAR-T) cells among other cellular modifications and treatments.

Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.

Provided are beads for blood processing having porous beads and a polymer carried on the surface of the porous beads, wherein: the porous beads are configured from at least one resin selected from the group consisting of acrylic resins, styrene resins, and cellulose resins; and the polymer includes a specific monomer defined in the description as a monomer unit.

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein.

The present invention relates to removal of protein bound deleterious substances from an extracorporeal biological fluid by changing the affinity of the substance to the protein. The invention relates to the use of displacer substances for removal of deleterious substances. The present invention also relate to a method of removal, a system, a cleaning fluid comprising the displacer substances for removal of deleterious substances.

A plasmapheresis device includes a column or other flow mechanism in which plasma lows following separation of the plasma from cellular components like blood cells, platelets and the like. The column includes a moiety, such as an antibody, which selectively binds to galectin-3. By removing galectin-3 from the blood stream of a mammal by at least 10%, improvements in the treatment of inflammation, suppression of the formation of fibroses, and a variety of cancer treatments can be effected or improved. The device provides tor multiple columns to remove a variety of elements but includes one which selectively removes galectin-3 from the blood flow. Other agents may be added to the plasma before recombination with the cellular components of the blood, and before returning the recombined flow to the patient.

The present invention provides for a method and apparatus for inserting and using dermal interstitial sensors in, for example, an analyte monitoring system, and for injecting active pharmaceutical ingredients, a bio-artificial organ device, and detection of a protein biomarker.

Methods of priming a plasma processing system are disclosed. The plasma processing system has a number of different fluid flow circuits that are defined by sources of fluid, fluid flow paths, waste containers, a mixer, a separator, valves and a pump. A first fluid circuit is flushed, where the first fluid circuit is defined by a source of a first fluid, a first valve positioned between the source of the first fluid and the first fluid flow path, a second valve positioned between the first fluid flow path and the second fluid flow path, a first pump positioned between the second fluid flow path and the third fluid flow path, and a first waste container in fluid communication with the third fluid flow path. A second fluid circuit is then flushed by closing and opening certain valves.